Total: $2.5M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@

Cerus Corp. (CERS)

Loan financing



Cerus secured a $50M loan commitment from a subsidiary of Baxter Healthcare Corp.; Cerus will be able to draw down on some or all of the unrestricted five-year loan beginning in January (10/31)

Epoch Biosciences Inc. (EBIO)

Term loan and a line of credit



Epoch closed two financing agreements with Silicon Valley Bank, including a $2.5M term loan and a $750,000 working capital line of credit; the term loan can be drawn through June 2003 (10/1)

Hemosol Inc. (Canada; HMSL; TSE:HML)

Loan financing



Hemosol has access to a C$20M (US$12.8M) loan from the Bank of Nova Scotia; MDS Inc. is providing the guarantee for the loan in return for 5M warrants to purchase common shares of Hemosol that are immediately exercisable at C$1 each (10/28)

Interleukin Genetics Inc. (ILGN)

Promissory notes



Interleukin Genetics raised $1.5M with a financing in the form of three $500,000 promissory notes (10/24)

Prescient NeuroPharma Inc. (Canada; CDNX:PRE)

Bridge financing agreement



Prescient concluded a bridge financing agreement with GeneChem Technologies Venture Fund LP, the Business Development Bank of Canada and Peter Allard for up to $1M (10/16)

SIGA Technologies Inc. (SIGA)

Private placement of units consisting of shares and warrants

1.04S and W for 0.5S


SIGA raised $1M in the private placement of units consisting of 1.04M shares and warrants to purchase 518,750 shares of stock at $2.25 per share (10/7)


This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

N/A = Not available, applicable or reported.

CDNX = Canadian Venture Exchange; TSE = Toronto Stock Exchange